{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T16:00:31Z","timestamp":1790438431141,"version":"4.1.0"},"reference-count":352,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100017599","name":"Science and Technology Program of Zhejiang Province","doi-asserted-by":"publisher","award":["WKJ-ZJ-2201"],"award-info":[{"award-number":["WKJ-ZJ-2201"]}],"id":[{"id":"10.13039\/501100017599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008867","name":"Department of Education of Zhejiang Province","doi-asserted-by":"publisher","award":["KYQN2025011"],"award-info":[{"award-number":["KYQN2025011"]}],"id":[{"id":"10.13039\/501100008867","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LMS25H160003"],"award-info":[{"award-number":["LMS25H160003"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.intimp.2026.117338","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T21:07:50Z","timestamp":1787951270000},"page":"117338","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Targeting immunosuppressive tumor microenvironment to combat immunotherapy resistance: From mechanistic insights to therapeutic strategies"],"prefix":"10.1016","volume":"188","author":[{"given":"Pengfei","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Mou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.intimp.2026.117338_bb0005","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.intimp.2026.117338_bb0010","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cell.2018.09.035","article-title":"A paradigm shift in cancer immunotherapy: from enhancement to normalization","volume":"175","author":"Sanmamed","year":"2018","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb0015","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-022-01282-8","article-title":"Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets","volume":"15","author":"Tie","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2026.117338_bb0020","article-title":"Myeloid-derived suppressor cells in cancer: mechanistic insights and targeted therapeutic innovations","volume":"6","author":"Hu","year":"2025","journal-title":"MedComm (2020)"},{"key":"10.1016\/j.intimp.2026.117338_bb0025","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.matbio.2024.06.004","article-title":"Cancer-associated fibroblasts promote proliferation, angiogenesis, metastasis and immunosuppression in gastric cancer","volume":"132","author":"Li","year":"2024","journal-title":"Matrix Biol."},{"key":"10.1016\/j.intimp.2026.117338_bb0030","doi-asserted-by":"crossref","first-page":"13720","DOI":"10.1038\/ncomms13720","article-title":"The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity","volume":"7","author":"Laoui","year":"2016","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.intimp.2026.117338_bb0035","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.immuni.2018.01.007","article-title":"Human T cell development, localization, and function throughout life","volume":"48","author":"Kumar","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2026.117338_bb0040","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.semcancer.2019.07.017","article-title":"Acquired resistance to cancer immunotherapy: role of tumor-mediated immunosuppression","volume":"65","author":"Saleh","year":"2020","journal-title":"Semin. Cancer Biol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb0045","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1146\/annurev-immunol-101819-024752","article-title":"Beyond the barrier: unraveling the mechanisms of immunotherapy resistance","volume":"42","author":"Bell","year":"2024","journal-title":"Annu. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb0050","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol. Cancer"},{"issue":"7","key":"10.1016\/j.intimp.2026.117338_bb0055","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1007\/s00262-023-03395-6","article-title":"LILRB2-containing small extracellular vesicles from glioblastoma promote tumor progression by promoting the formation and expansion of myeloid-derived suppressor cells","volume":"72","author":"Wu","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb0060","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12943-021-01486-5","article-title":"Immunometabolic rewiring in tumorigenesis and anti-tumor immunotherapy","volume":"21","author":"Lian","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.intimp.2026.117338_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105301","article-title":"Reprogramming the immunosuppressive tumor microenvironment through nanomedicine: an immunometabolism perspective","volume":"107","author":"Liu","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.intimp.2026.117338_bb0070","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.semcancer.2019.09.004","article-title":"Emerging roles of ECM remodeling processes in cancer","volume":"62","author":"Mohan","year":"2020","journal-title":"Semin. Cancer Biol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb0075","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12943-024-02064-1","article-title":"Decoding the spatiotemporal heterogeneity of tumor-associated macrophages","volume":"23","author":"Chu","year":"2024","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb0080","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1186\/s12967-022-03813-w","article-title":"Targeting macrophages: a novel treatment strategy in solid tumors","volume":"20","author":"Liu","year":"2022","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb0085","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1186\/s12935-022-02717-5","article-title":"Crosstalk between tumor-associated macrophages and tumor cells promotes chemoresistance via CXCL5\/PI3K\/AKT\/mTOR pathway in gastric cancer","volume":"22","author":"Su","year":"2022","journal-title":"Cancer Cell Int."},{"issue":"10","key":"10.1016\/j.intimp.2026.117338_bb0090","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009983","article-title":"SPI1+CD68+ macrophages as a biomarker for gastric cancer metastasis: a rationale for combined antiangiogenic and immunotherapy strategies","volume":"12","author":"Deng","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.intimp.2026.117338_bb0095","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.intimp.2026.117338_bb0100","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13115","article-title":"Role of the CCL2-CCR2 signalling axis in cancer: mechanisms and therapeutic targeting","volume":"54","author":"Xu","year":"2021","journal-title":"Cell Prolif."},{"issue":"13","key":"10.1016\/j.intimp.2026.117338_bb0105","doi-asserted-by":"crossref","first-page":"4884","DOI":"10.7150\/ijbs.74647","article-title":"Tumor-associated macrophage-derived chemokine CCL5 facilitates the progression and immunosuppressive tumor microenvironment of clear cell renal cell carcinoma","volume":"18","author":"Xu","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.intimp.2026.117338_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100718","article-title":"Cancer immunotherapy resistance based on immune checkpoints inhibitors: targets, biomarkers, and remedies","volume":"53","author":"P\u00e9rez-Ruiz","year":"2020","journal-title":"Drug Resist. Updat."},{"issue":"7858","key":"10.1016\/j.intimp.2026.117338_bb0115","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41586-021-03442-1","article-title":"Cell-programmed nutrient partitioning in the tumour microenvironment","volume":"593","author":"Reinfeld","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2026.117338_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114504","article-title":"The role of metabolic reprogramming of tumor-associated macrophages in shaping the immunosuppressive tumor microenvironment","volume":"161","author":"Li","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"12","key":"10.1016\/j.intimp.2026.117338_bb0125","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.it.2022.10.005","article-title":"Lactic acid and lactate: revisiting the physiological roles in the tumor microenvironment","volume":"43","author":"Apostolova","year":"2022","journal-title":"Trends Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb0130","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","article-title":"Myeloid-derived suppressor cells","volume":"5","author":"Gabrilovich","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"19","key":"10.1016\/j.intimp.2026.117338_bb0135","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1158\/0008-5472.CAN-23-0046","article-title":"Galectin-1 mediates chronic STING activation in tumors to promote metastasis through MDSC recruitment","volume":"83","author":"Nambiar","year":"2023","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.intimp.2026.117338_bb0140","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb0145","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","article-title":"Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb0150","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12943-022-01657-y","article-title":"Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy","volume":"21","author":"Wu","year":"2022","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2026.117338_bb0155","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000949","article-title":"IL-6 regulates CCR5 expression and immunosuppressive capacity of MDSC in murine melanoma","volume":"8","author":"Weber","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2026.117338_bb0160","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.canlet.2020.03.013","article-title":"Myeloid-derived suppressor cells are essential partners for immune checkpoint inhibitors in the treatment of cisplatin-resistant bladder cancer","volume":"479","author":"Takeyama","year":"2020","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb0165","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12943-024-02208-3","article-title":"Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy","volume":"24","author":"He","year":"2025","journal-title":"Mol. Cancer"},{"issue":"15","key":"10.1016\/j.intimp.2026.117338_bb0170","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1158\/1078-0432.CCR-14-0635","article-title":"Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity","volume":"20","author":"Mao","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.intimp.2026.117338_bb0175","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/hep.23054","article-title":"Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor","volume":"50","author":"Hoechst","year":"2009","journal-title":"Hepatology"},{"issue":"15","key":"10.1016\/j.intimp.2026.117338_bb0180","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.138581","article-title":"Polymorphonuclear myeloid-derived suppressor cells limit antigen cross-presentation by dendritic cells in cancer","volume":"5","author":"Ugolini","year":"2020","journal-title":"JCI Insight"},{"issue":"13","key":"10.1016\/j.intimp.2026.117338_bb0185","doi-asserted-by":"crossref","DOI":"10.1172\/JCI170762","article-title":"Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target","volume":"133","author":"Ozbay Kurt","year":"2023","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.intimp.2026.117338_bb0190","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","article-title":"Regulatory T cells in cancer immunosuppression-implications for anticancer therapy","volume":"16","author":"Togashi","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2026.117338_bb0195","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2023.02.014","article-title":"Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy","volume":"41","author":"Tay","year":"2023","journal-title":"Cancer Cell"},{"issue":"5899","key":"10.1016\/j.intimp.2026.117338_bb0200","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1126\/science.1160062","article-title":"CTLA-4 control over Foxp3+ regulatory T cell function","volume":"322","author":"Wing","year":"2008","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.intimp.2026.117338_bb0205","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/nri3108","article-title":"The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses","volume":"11","author":"Walker","year":"2011","journal-title":"Nat. Rev. Immunol."},{"issue":"6029","key":"10.1016\/j.intimp.2026.117338_bb0210","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1126\/science.1202947","article-title":"Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4","volume":"332","author":"Qureshi","year":"2011","journal-title":"Science"},{"issue":"30","key":"10.1016\/j.intimp.2026.117338_bb0215","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2023739118","article-title":"Treg-expressed CTLA-4 depletes CD80\/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells","volume":"118","author":"Tekguc","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"10","key":"10.1016\/j.intimp.2026.117338_bb0220","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41577-018-0046-y","article-title":"Biology and regulation of IL-2: from molecular mechanisms to human therapy","volume":"18","author":"Spolski","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb0225","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20191247","article-title":"Effects of interleukin-2 in immunostimulation and immunosuppression","volume":"217","author":"Pol","year":"2020","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb0230","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/imr.12528","article-title":"The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets","volume":"276","author":"Allard","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.intimp.2026.117338_bb0235","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.914799","article-title":"The multifaceted actions of CD73 during development and suppressive actions of regulatory T cells","volume":"13","author":"Da","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117338_bb0240","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1387975","article-title":"Regulation of Treg cells by cytokine signaling and co-stimulatory molecules","volume":"15","author":"Zong","year":"2024","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2026.117338_bb0245","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.7150\/jca.29170","article-title":"Interleukin-35 as an emerging player in tumor microenvironment","volume":"10","author":"Xue","year":"2019","journal-title":"J. Cancer"},{"issue":"6","key":"10.1016\/j.intimp.2026.117338_bb0250","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nm.4086","article-title":"Two FOXP3(+) CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers","volume":"22","author":"Saito","year":"2016","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.intimp.2026.117338_bb0255","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.immuni.2007.08.014","article-title":"Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance","volume":"27","author":"Cao","year":"2007","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.intimp.2026.117338_bb0260","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s44321-025-00200-y","article-title":"Lanatoside C activates the E3 ligase STUB1 to inhibit FOXP3 transcriptional activity and promote antitumor immunity","volume":"17","author":"Zhou","year":"2025","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.intimp.2026.117338_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217475","article-title":"FAP upregulates PD-L1 expression in cancer-associated fibroblasts to exacerbate T cells dysfunction and suppress anti-tumor immunity","volume":"612","author":"Wei","year":"2025","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb0270","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/s41467-018-03347-0","article-title":"Cancer-associated fibroblasts induce antigen-specific deletion of CD8 + T Cells to protect tumour cells","volume":"9","author":"Lakins","year":"2018","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.intimp.2026.117338_bb0275","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1158\/0008-5472.CAN-23-1448","article-title":"Spatial and single-cell transcriptomics reveal a cancer-associated fibroblast subset in HNSCC that restricts infiltration and antitumor activity of CD8+ T cells","volume":"84","author":"Li","year":"2024","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb0280","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1158\/2326-6066.CIR-21-1088","article-title":"Extracellular galectin 4 drives immune evasion and promotes T-cell apoptosis in pancreatic cancer","volume":"11","author":"Lidstr\u00f6m","year":"2023","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb0285","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1038\/s41598-019-39553-z","article-title":"Cancer associated fibroblasts sculpt tumour microenvironment by recruiting monocytes and inducing immunosuppressive PD-1+ TAMs","volume":"9","author":"Yavuz","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2026.117338_bb0290","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.canlet.2021.07.006","article-title":"Stromal fibroblasts shape the myeloid phenotype in normal colon and colorectal cancer and induce CD163 and CCL2 expression in macrophages","volume":"520","author":"Stadler","year":"2021","journal-title":"Cancer Lett."},{"issue":"7655","key":"10.1016\/j.intimp.2026.117338_bb0295","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.intimp.2026.117338_bb0300","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.canlet.2011.12.020","article-title":"Hepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and IDO","volume":"318","author":"Li","year":"2012","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb0305","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","article-title":"Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives","volume":"20","author":"Mao","year":"2021","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2026.117338_bb0310","doi-asserted-by":"crossref","DOI":"10.1038\/oncsis.2016.7","article-title":"Hepatic carcinoma-associated fibroblasts induce IDO-producing regulatory dendritic cells through IL-6-mediated STAT3 activation","volume":"5","author":"Cheng","year":"2016","journal-title":"Oncogenesis"},{"key":"10.1016\/j.intimp.2026.117338_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102843","article-title":"Crosstalk and communication of cancer-associated fibroblasts with natural killer and dendritic cells: new frontiers and unveiled opportunities for cancer immunotherapy","volume":"131","author":"Ielpo","year":"2024","journal-title":"Cancer Treat. Rev."},{"issue":"2","key":"10.1016\/j.intimp.2026.117338_bb0320","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/gutjnl-2020-322924","article-title":"Targeting cancer-associated fibroblast-secreted WNT2 restores dendritic cell-mediated antitumour immunity","volume":"71","author":"Huang","year":"2022","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.intimp.2026.117338_bb0325","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/cas.12099","article-title":"Forkhead box P3 regulatory T cells coexisting with cancer associated fibroblasts are correlated with a poor outcome in lung adenocarcinoma","volume":"104","author":"Kinoshita","year":"2013","journal-title":"Cancer Sci."},{"issue":"7","key":"10.1016\/j.intimp.2026.117338_bb0330","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1440167","article-title":"Unveiling a CD70-positive subset of cancer-associated fibroblasts marked by pro-migratory activity and thriving regulatory T cell accumulation","volume":"7","author":"Jacobs","year":"2018","journal-title":"Oncoimmunology"},{"issue":"4","key":"10.1016\/j.intimp.2026.117338_bb0335","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.ajpath.2019.12.007","article-title":"Diminished CD68+ cancer-associated fibroblast subset induces regulatory T-cell (Treg) infiltration and predicts poor prognosis of oral squamous cell carcinoma patients","volume":"190","author":"Zhao","year":"2020","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb0340","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12943-023-01731-z","article-title":"Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1\/PD-L1 immunotherapy for solid cancers","volume":"22","author":"Pei","year":"2023","journal-title":"Mol. Cancer"},{"issue":"6","key":"10.1016\/j.intimp.2026.117338_bb0345","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/ncb2756","article-title":"Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts","volume":"15","author":"Calvo","year":"2013","journal-title":"Nat. Cell Biol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb0350","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1038\/s41467-018-06654-8","article-title":"TGF-\u03b2-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure","volume":"9","author":"Chakravarthy","year":"2018","journal-title":"Nat. Commun."},{"issue":"39","key":"10.1016\/j.intimp.2026.117338_bb0355","doi-asserted-by":"crossref","first-page":"19609","DOI":"10.1073\/pnas.1908626116","article-title":"Proteomic analyses of ECM during pancreatic ductal adenocarcinoma progression reveal different contributions by tumor and stromal cells","volume":"116","author":"Tian","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.intimp.2026.117338_bb0360","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3389\/fimmu.2015.00500","article-title":"Real-time imaging of resident T cells in human lung and ovarian carcinomas reveals how different tumor microenvironments control T lymphocyte migration","volume":"6","author":"Bougherara","year":"2015","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2026.117338_bb0365","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nm.4123","article-title":"Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy","volume":"22","author":"Jiang","year":"2016","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb0370","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40425-018-0376-0","article-title":"Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers","volume":"6","author":"Mushtaq","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb0375","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41423-021-00741-5","article-title":"Dendritic cells in cancer immunology","volume":"19","author":"Murphy","year":"2022","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.intimp.2026.117338_bb0380","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.pharmthera.2016.04.003","article-title":"State-of-the-art of regulatory dendritic cells in cancer","volume":"164","author":"Conejo-Garcia","year":"2016","journal-title":"Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.intimp.2026.117338_bb0385","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1189\/jlb.4MR1116-466R","article-title":"Exploiting tumor-associated dendritic cell heterogeneity for novel cancer therapies","volume":"102","author":"Keirsse","year":"2017","journal-title":"J. Leukoc. Biol."},{"issue":"7","key":"10.1016\/j.intimp.2026.117338_bb0390","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.3390\/ijms24076501","article-title":"Galectin-1: A traditionally immunosuppressive protein displays context-dependent capacities","volume":"24","author":"Yu","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.intimp.2026.117338_bb0395","doi-asserted-by":"crossref","first-page":"6905","DOI":"10.4049\/jimmunol.1100274","article-title":"Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer","volume":"186","author":"Krempski","year":"2011","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2026.117338_bb0400","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/nm.2172","article-title":"Lipid accumulation and dendritic cell dysfunction in cancer","volume":"16","author":"Herber","year":"2010","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb0405","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/s12935-022-02727-3","article-title":"Tumor-promoting myeloid cells in the pathogenesis of human oncoviruses: potential targets for immunotherapy","volume":"22","author":"Aghamajidi","year":"2022","journal-title":"Cancer Cell Int."},{"issue":"11","key":"10.1016\/j.intimp.2026.117338_bb0410","doi-asserted-by":"crossref","first-page":"5862","DOI":"10.1039\/D3CS00602F","article-title":"Engineered biological nanoparticles as nanotherapeutics for tumor immunomodulation","volume":"53","author":"Rahmat","year":"2024","journal-title":"Chem. Soc. Rev."},{"issue":"8","key":"10.1016\/j.intimp.2026.117338_bb0415","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1172\/JCI127201","article-title":"Adipocyte and lipid metabolism in cancer drug resistance","volume":"129","author":"Cao","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2026.117338_bb0420","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1146\/annurev-pathol-012615-044359","article-title":"Obesity, inflammation, and cancer","volume":"11","author":"Deng","year":"2016","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.intimp.2026.117338_bb0425","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.656364","article-title":"Aspects of the tumor microenvironment involved in immune resistance and drug resistance","volume":"12","author":"Khalaf","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb0430","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1186\/s12885-023-10826-1","article-title":"CAA-derived IL-6 induced M2 macrophage polarization by activating STAT3","volume":"23","author":"Zhao","year":"2023","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb0435","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1969075","article-title":"Stromal infiltrating mast cells identify immunoevasive subtype high-grade serous ovarian cancer with poor prognosis and inferior immunotherapeutic response","volume":"10","author":"Cao","year":"2021","journal-title":"Oncoimmunology"},{"issue":"14","key":"10.1016\/j.intimp.2026.117338_bb0440","article-title":"The crosstalk with CXCL10-rich tumor-associated mast cells fuels pancreatic cancer progression and immune escape","volume":"12","author":"Yin","year":"2025","journal-title":"Adv. Sci (Weinh)."},{"issue":"4","key":"10.1016\/j.intimp.2026.117338_bb0445","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.immuni.2015.04.005","article-title":"Regulatory B cells: origin, phenotype, and function","volume":"42","author":"Rosser","year":"2015","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.intimp.2026.117338_bb0450","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41568-022-00466-1","article-title":"Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities","volume":"22","author":"Laumont","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb0455","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/imr.12939","article-title":"Regulatory B cells in cancer","volume":"299","author":"Michaud","year":"2021","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.intimp.2026.117338_bb0460","article-title":"Plasma PFDN2 suppresses head and neck squamous cell carcinoma progression by restricting CD64 on monocyte-driven inflammatory microenvironments","volume":"17","author":"Feng","year":"2026","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2026.117338_bb0465","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.immuni.2024.02.007","article-title":"CD4+ T cell activation distinguishes response to anti-PD-L1+anti-CTLA4 therapy from anti-PD-L1 monotherapy","volume":"57","author":"Franken","year":"2024","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb0470","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12929-024-00998-8","article-title":"Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategies","volume":"31","author":"Li","year":"2024","journal-title":"J. Biomed. Sci."},{"issue":"38","key":"10.1016\/j.intimp.2026.117338_bb0475","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd2712","article-title":"Revisiting the PD-1 pathway","volume":"6","author":"Patsoukis","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.intimp.2026.117338_bb0480","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev-immunol-070621-030155","article-title":"Resistance mechanisms to anti-PD cancer immunotherapy","volume":"40","author":"Vesely","year":"2022","journal-title":"Annu. Rev. Immunol."},{"issue":"18","key":"10.1016\/j.intimp.2026.117338_bb0485","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD-1 checkpoint pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2026.117338_bb0490","doi-asserted-by":"crossref","first-page":"550","DOI":"10.3389\/fimmu.2016.00550","article-title":"The PD1:PD-L1\/2 pathway from discovery to clinical implementation","volume":"7","author":"Bardhan","year":"2016","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2026.117338_bb0495","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.immuni.2016.07.008","article-title":"Bioenergetic insufficiencies due to metabolic alterations regulated by the inhibitory receptor PD-1 are an early driver of CD8(+) T cell exhaustion","volume":"45","author":"Bengsch","year":"2016","journal-title":"Immunity"},{"issue":"23","key":"10.1016\/j.intimp.2026.117338_bb0500","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.4161\/cc.22135","article-title":"PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A","volume":"11","author":"Patsoukis","year":"2012","journal-title":"Cell Cycle"},{"issue":"13","key":"10.1016\/j.intimp.2026.117338_bb0505","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb0510","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1186\/s12967-025-06469-4","article-title":"PD-1 regulates the anti-tumor immune function of macrophages through JAK2-STAT3 signaling pathway in colorectal cancer tumor microenvironment","volume":"23","author":"Jiang","year":"2025","journal-title":"J. Transl. Med."},{"issue":"2","key":"10.1016\/j.intimp.2026.117338_bb0515","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2016.33","article-title":"Attenuation of the programmed cell death-1 pathway increases the M1 polarization of macrophages induced by zymosan","volume":"7","author":"Chen","year":"2016","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.intimp.2026.117338_bb0520","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.jaci.2018.02.050","article-title":"PD-1 blocks lytic granule polarization with concomitant impairment of integrin outside-in signaling in the natural killer cell immunological synapse","volume":"142","author":"Huang","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb0525","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: a moving target in immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.intimp.2026.117338_bb0530","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.cell.2009.05.015","article-title":"SnapShot: B7\/CD28 costimulation","volume":"137","author":"Paterson","year":"2009","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.intimp.2026.117338_bb0535","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1080\/13543776.2025.2462849","article-title":"Small molecules targeting immune checkpoint proteins for cancer immunotherapy: a patent and literature review (2020-2024)","volume":"35","author":"Geng","year":"2025","journal-title":"Expert Opin. Ther. Pat."},{"issue":"5","key":"10.1016\/j.intimp.2026.117338_bb0540","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.immuni.2016.04.020","article-title":"CD28 costimulation: from mechanism to therapy","volume":"44","author":"Esensten","year":"2016","journal-title":"Immunity"},{"issue":"21","key":"10.1016\/j.intimp.2026.117338_bb0545","doi-asserted-by":"crossref","first-page":"E4223","DOI":"10.1073\/pnas.1617941114","article-title":"Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab","volume":"114","author":"Ramagopal","year":"2017","journal-title":"Pro. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.intimp.2026.117338_bb0550","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1159\/000490025","article-title":"Evolving roles for targeting CTLA-4 in cancer immunotherapy","volume":"47","author":"Zhao","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"issue":"3","key":"10.1016\/j.intimp.2026.117338_bb0555","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S1074-7613(00)00031-5","article-title":"The CD28 and CTLA-4 receptors associate with the serine\/threonine phosphatase PP2A","volume":"13","author":"Chuang","year":"2000","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.intimp.2026.117338_bb0560","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.immuni.2024.01.013","article-title":"The B7:CD28 family and friends: unraveling coinhibitory interactions","volume":"57","author":"Burke","year":"2024","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.intimp.2026.117338_bb0565","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1200\/JCO.19.02988","article-title":"Another victory for immune checkpoint blockade in melanoma: adjuvant ipilimumab over interferon","volume":"38","author":"Warner","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb0570","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s43556-025-00267-6","article-title":"TIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives","volume":"6","author":"Yan","year":"2025","journal-title":"Mol. Biomed."},{"issue":"6871","key":"10.1016\/j.intimp.2026.117338_bb0575","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/415536a","article-title":"Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease","volume":"415","author":"Monney","year":"2002","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.intimp.2026.117338_bb0580","doi-asserted-by":"crossref","DOI":"10.4161\/onci.23849","article-title":"TIM3+FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer","volume":"2","author":"Sakuishi","year":"2013","journal-title":"Oncoimmunology"},{"issue":"9","key":"10.1016\/j.intimp.2026.117338_bb0585","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/ni.2376","article-title":"Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1","volume":"13","author":"Chiba","year":"2012","journal-title":"Nat. Immunol."},{"issue":"16","key":"10.1016\/j.intimp.2026.117338_bb0590","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1182\/blood-2011-11-392951","article-title":"Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity","volume":"119","author":"Ndhlovu","year":"2012","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.intimp.2026.117338_bb0595","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1211219","article-title":"Tim-3 promotes tumor-promoting M2 macrophage polarization by binding to STAT1 and suppressing the STAT1-miR-155 signaling axis","volume":"5","author":"Jiang","year":"2016","journal-title":"Oncoimmunology"},{"issue":"3","key":"10.1016\/j.intimp.2026.117338_bb0600","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","article-title":"TIM3 comes of age as an inhibitory receptor","volume":"20","author":"Wolf","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb0605","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/imr.12520","article-title":"Tim-3 and its role in regulating anti-tumor immunity","volume":"276","author":"Das","year":"2017","journal-title":"Immunol. Rev."},{"issue":"2","key":"10.1016\/j.intimp.2026.117338_bb0610","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.bbrc.2006.10.079","article-title":"A highly conserved tyrosine of Tim-3 is phosphorylated upon stimulation by its ligand galectin-9","volume":"351","author":"van de Weyer","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"19","key":"10.1016\/j.intimp.2026.117338_bb0615","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1128\/MCB.05297-11","article-title":"Phosphotyrosine-dependent coupling of Tim-3 to T-cell receptor signaling pathways","volume":"31","author":"Lee","year":"2011","journal-title":"Mol. Cell. Biol."},{"issue":"9","key":"10.1016\/j.intimp.2026.117338_bb0620","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/nm.2871","article-title":"Bat3 promotes T cell responses and autoimmunity by repressing Tim-3\u2013mediated cell death and exhaustion","volume":"18","author":"Rangachari","year":"2012","journal-title":"Nat. Med."},{"issue":"7534","key":"10.1016\/j.intimp.2026.117338_bb0625","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nature13848","article-title":"CEACAM1 regulates TIM-3-mediated tolerance and exhaustion","volume":"517","author":"Huang","year":"2015","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.intimp.2026.117338_bb0630","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1128\/MCB.01983-06","article-title":"PAG-associated FynT regulates calcium signaling and promotes anergy in T lymphocytes","volume":"27","author":"Davidson","year":"2007","journal-title":"Mol. Cell. Biol."},{"issue":"10","key":"10.1016\/j.intimp.2026.117338_bb0635","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1016\/j.celrep.2016.11.035","article-title":"The Csk-associated adaptor PAG inhibits effector T cell activation in cooperation with phosphatase PTPN22 and Dok adaptors","volume":"17","author":"Davidson","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.intimp.2026.117338_bb0640","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.canlet.2021.04.011","article-title":"The TIM3\/Gal9 signaling pathway: an emerging target for cancer immunotherapy","volume":"510","author":"Kandel","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2026.117338_bb0645","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.cellimm.2017.01.001","article-title":"Tumor antigen-specific CD8+ T cells are negatively regulated by PD-1 and Tim-3 in human gastric cancer","volume":"313","author":"Lu","year":"2017","journal-title":"Cell. Immunol."},{"issue":"13","key":"10.1016\/j.intimp.2026.117338_bb0650","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1158\/1078-0432.CCR-20-4746","article-title":"Phase I\/Ib clinical trial of sabatolimab, an anti-TIM-3 antibody, alone and in combination with spartalizumab, an anti-PD-1 antibody, in advanced solid tumors","volume":"27","author":"Curigliano","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb0655","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/ni.1674","article-title":"The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells","volume":"10","author":"Yu","year":"2009","journal-title":"Nat. Immunol."},{"issue":"14","key":"10.1016\/j.intimp.2026.117338_bb0660","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1073\/pnas.1120606109","article-title":"Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell-cell adhesion and signaling mechanism that requires cis-trans receptor clustering","volume":"109","author":"Stengel","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.intimp.2026.117338_bb0665","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"issue":"22","key":"10.1016\/j.intimp.2026.117338_bb0670","doi-asserted-by":"crossref","first-page":"6375","DOI":"10.1158\/0008-5472.CAN-17-0381","article-title":"CD155T\/TIGIT signaling regulates CD8+ T-cell metabolism and promotes tumor progression in human gastric cancer","volume":"77","author":"He","year":"2017","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.intimp.2026.117338_bb0675","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/cei.13407","article-title":"TIGIT as an emerging immune checkpoint","volume":"200","author":"Harjunp\u00e4\u00e4","year":"2020","journal-title":"Clin. Exp. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb0680","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","article-title":"Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy","volume":"16","author":"Cai","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.intimp.2026.117338_bb0685","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.4049\/jimmunol.1103627","article-title":"The TIGIT\/CD226 axis regulates human T cell function","volume":"188","author":"Lozano","year":"2012","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2026.117338_bb0690","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004711","article-title":"TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy","volume":"10","author":"Chiang","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.intimp.2026.117338_bb0695","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","article-title":"The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function","volume":"26","author":"Johnston","year":"2014","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb0700","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1038\/s41467-025-57603-1","article-title":"Interleukin-16 enhances anti-tumor immune responses by establishing a Th1 cell-macrophage crosstalk through reprogramming glutamine metabolism in mice","volume":"16","author":"Wen","year":"2025","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.intimp.2026.117338_bb0705","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.immuni.2014.02.012","article-title":"Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses","volume":"40","author":"Joller","year":"2014","journal-title":"Immunity"},{"issue":"25","key":"10.1016\/j.intimp.2026.117338_bb0710","doi-asserted-by":"crossref","first-page":"17647","DOI":"10.1074\/jbc.M114.572420","article-title":"T-cell immunoglobulin and ITIM domain (TIGIT) receptor\/poliovirus receptor (PVR) ligand engagement suppresses interferon-\u03b3 production of natural killer cells via \u03b2-arrestin 2-mediated negative signaling","volume":"289","author":"Li","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.intimp.2026.117338_bb0715","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1172\/JCI80445","article-title":"TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients","volume":"125","author":"Chauvin","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.intimp.2026.117338_bb0720","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001014","article-title":"LAG-3: from molecular functions to clinical applications","volume":"8","author":"Maruhashi","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"17","key":"10.1016\/j.intimp.2026.117338_bb0725","doi-asserted-by":"crossref","first-page":"9958","DOI":"10.3390\/ijms23179958","article-title":"LAG-3 as a potent target for novel anticancer therapies of a wide range of tumors","volume":"23","author":"Sauer","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.intimp.2026.117338_bb0730","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/s41590-022-01238-7","article-title":"LAG3 ectodomain structure reveals functional interfaces for ligand and antibody recognition","volume":"23","author":"Ming","year":"2022","journal-title":"Nat. Immunol."},{"issue":"1\u20132","key":"10.1016\/j.intimp.2026.117338_bb0735","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.cell.2018.11.010","article-title":"Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3","volume":"176","author":"Wang","year":"2019","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.intimp.2026.117338_bb0740","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1158\/2326-6066.CIR-14-0150","article-title":"Galectin-3 shapes antitumor immune responses by suppressing CD8+ T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells","volume":"3","author":"Kouo","year":"2015","journal-title":"Cancer Immunol. Res."},{"issue":"13","key":"10.1016\/j.intimp.2026.117338_bb0745","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1158\/0008-5472.CAN-13-2690","article-title":"LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses","volume":"74","author":"Xu","year":"2014","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb0750","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/imm.13001","article-title":"VSIG-3 as a ligand of VISTA inhibits human T-cell function","volume":"156","author":"Wang","year":"2019","journal-title":"Immunology"},{"issue":"3","key":"10.1016\/j.intimp.2026.117338_bb0755","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2025.189351","article-title":"VISTA as a context-dependent immune checkpoint: implications for tumor immunity and autoimmune pathogenesis","volume":"1880","author":"Niu","year":"2025","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"7","key":"10.1016\/j.intimp.2026.117338_bb0760","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1158\/0008-5472.CAN-13-1506","article-title":"VISTA regulates the development of protective antitumor immunity","volume":"74","author":"Mercier","year":"2014","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.intimp.2026.117338_bb0765","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1038\/modpathol.2017.89","article-title":"Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients","volume":"30","author":"Kakavand","year":"2017","journal-title":"Mod. Pathol."},{"issue":"9","key":"10.1016\/j.intimp.2026.117338_bb0770","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1158\/2326-6066.CIR-18-0489","article-title":"Immune-checkpoint protein VISTA regulates antitumor immunity by controlling myeloid cell-mediated inflammation and immunosuppression","volume":"7","author":"Xu","year":"2019","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb0775","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13046-020-01820-7","article-title":"Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy","volume":"40","author":"Wang","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.intimp.2026.117338_bb0780","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.1172\/JCI96268","article-title":"Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy","volume":"128","author":"Jayaprakash","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2026.117338_bb0785","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103627","article-title":"Lactate in the tumour microenvironment: from immune modulation to therapy","volume":"73","author":"Wang","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.intimp.2026.117338_bb0790","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.semcancer.2022.12.011","article-title":"Tumor hypoxia: from basic knowledge to therapeutic implications","volume":"88","author":"Liao","year":"2023","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.intimp.2026.117338_bb0795","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.redox.2015.09.022","article-title":"Mechanisms of hypoxia-induced immune escape in cancer and their regulation by nitric oxide","volume":"5","author":"Graham","year":"2015","journal-title":"Redox Biol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb0800","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1038\/s41467-022-31764-9","article-title":"Hypoxia induces HIF1\u03b1-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy","volume":"13","author":"Ma","year":"2022","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.intimp.2026.117338_bb0805","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1158\/0008-5472.CAN-13-0992","article-title":"A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells","volume":"74","author":"Barsoum","year":"2014","journal-title":"Cancer Res."},{"issue":"41","key":"10.1016\/j.intimp.2026.117338_bb0810","doi-asserted-by":"crossref","first-page":"E2784","DOI":"10.1073\/pnas.1202366109","article-title":"Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa","volume":"109","author":"Clambey","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"10","key":"10.1016\/j.intimp.2026.117338_bb0815","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1172\/JCI84427","article-title":"The impact of hypoxia on tumor-associated macrophages","volume":"126","author":"Henze","year":"2016","journal-title":"J. Clin. Invest."},{"issue":"16","key":"10.1016\/j.intimp.2026.117338_bb0820","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.7150\/thno.95766","article-title":"Hypoxia-driven M2-polarized macrophages facilitate the epithelial-mesenchymal transition of glioblastoma via extracellular vesicles","volume":"14","author":"Liu","year":"2024","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb0825","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1186\/s12967-025-06692-z","article-title":"Knocking down hypoxia-induced Semaphorin 6B may attenuate the progression of cervical cancer through regulating macrophage M2 polarization","volume":"23","author":"Yi","year":"2025","journal-title":"J. Transl. Med."},{"issue":"12","key":"10.1016\/j.intimp.2026.117338_bb0830","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.trecan.2019.10.007","article-title":"Metabolic regulation of macrophage polarization in cancer","volume":"5","author":"Mehla","year":"2019","journal-title":"Trends Cancer"},{"key":"10.1016\/j.intimp.2026.117338_bb0835","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.canlet.2017.10.037","article-title":"Metabolic changes in tumor cells and tumor-associated macrophages: a mutual relationship","volume":"413","author":"Netea-Maier","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2026.117338_bb0840","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112559","article-title":"Hypoxia-induced Semaphorin 3A promotes the development of endometriosis through regulating macrophage polarization","volume":"138","author":"Yang","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"3","key":"10.1016\/j.intimp.2026.117338_bb0845","first-page":"C449","article-title":"A distinct transcriptional profile in response to endothelial monocyte activating polypeptide II is partially mediated by JAK-STAT3 in murine macrophages","volume":"317","author":"Lee","year":"2019","journal-title":"Am. J. Phys. Cell Phys."},{"issue":"11","key":"10.1016\/j.intimp.2026.117338_bb0850","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1084\/jem.20100587","article-title":"HIF-1\u03b1 regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment","volume":"207","author":"Corzo","year":"2010","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.intimp.2026.117338_bb0855","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1158\/0008-5472.CAN-13-2584","article-title":"SIRT1 limits the function and fate of myeloid-derived suppressor cells in tumors by orchestrating HIF-1\u03b1-dependent glycolysis","volume":"74","author":"Liu","year":"2014","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.intimp.2026.117338_bb0860","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.immuni.2016.01.014","article-title":"CD45 phosphatase inhibits STAT3 transcription factor activity in myeloid cells and promotes tumor-associated macrophage differentiation","volume":"44","author":"Kumar","year":"2016","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.intimp.2026.117338_bb0865","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/hep.28655","article-title":"Hypoxia induces myeloid-derived suppressor cell recruitment to hepatocellular carcinoma through chemokine (C-C motif) ligand 26","volume":"64","author":"Chiu","year":"2016","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb0870","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41467-017-00530-7","article-title":"Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2\/CD39L1 in hepatocellular carcinoma","volume":"8","author":"Chiu","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2026.117338_bb0875","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1146\/annurev-immunol-100819-121537","article-title":"Hypoxia and innate immunity: keeping up with the HIFsters","volume":"38","author":"Colgan","year":"2020","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.intimp.2026.117338_bb0880","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.613492","article-title":"Metabolism of dendritic cells in tumor microenvironment: for immunotherapy","volume":"12","author":"Peng","year":"2021","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2026.117338_bb0885","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0244366","article-title":"Hypoxia-inducible factor 1 alpha limits dendritic cell stimulation of CD8 T cell immunity","volume":"15","author":"Tran","year":"2020","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.intimp.2026.117338_bb0890","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1038\/s41590-019-0511-1","article-title":"Mitochondrial fragmentation limits NK cell-based tumor immunosurveillance","volume":"20","author":"Zheng","year":"2019","journal-title":"Nat. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2026.117338_bb0895","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1002\/eji.201343448","article-title":"Hypoxia downregulates the expression of activating receptors involved in NK-cell-mediated target cell killing without affecting ADCC","volume":"43","author":"Balsamo","year":"2013","journal-title":"Eur. J. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2026.117338_bb0900","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cmet.2022.01.007","article-title":"The hallmarks of cancer metabolism: still emerging","volume":"34","author":"Pavlova","year":"2022","journal-title":"Cell Metab."},{"key":"10.1016\/j.intimp.2026.117338_bb0905","article-title":"Fundamentals of T cell metabolism and strategies to enhance cancer immunotherapy","volume":"12","author":"Rivera","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb0910","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.immuni.2014.12.030","article-title":"The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo","volume":"42","author":"Blagih","year":"2015","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.intimp.2026.117338_bb0915","doi-asserted-by":"crossref","first-page":"4670","DOI":"10.4049\/jimmunol.174.8.4670","article-title":"Glucose availability regulates IFN-gamma production and p70S6 kinase activation in CD8+ effector T cells","volume":"174","author":"Cham","year":"2005","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2026.117338_bb0920","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.4049\/jimmunol.1401558","article-title":"mTORC1-dependent metabolic reprogramming is a prerequisite for NK cell effector function","volume":"193","author":"Donnelly","year":"2014","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2026.117338_bb0925","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.cmet.2021.03.023","article-title":"Metabolic flexibility determines human NK cell functional fate in the tumor microenvironment","volume":"33","author":"Poznanski","year":"2021","journal-title":"Cell Metab."},{"issue":"7","key":"10.1016\/j.intimp.2026.117338_bb0930","doi-asserted-by":"crossref","DOI":"10.1172\/JCI166031","article-title":"Glycolysis drives STING signaling to facilitate dendritic cell antitumor function","volume":"133","author":"Hu","year":"2023","journal-title":"J. Clin. Invest."},{"issue":"7824","key":"10.1016\/j.intimp.2026.117338_bb0935","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41586-020-2682-1","article-title":"Cancer SLC43A2 alters T cell methionine metabolism and histone methylation","volume":"585","author":"Bian","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb0940","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1038\/s41467-023-38316-9","article-title":"Methionine consumption by cancer cells drives a progressive upregulation of PD-1 expression in CD4 T cells","volume":"14","author":"Pandit","year":"2023","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.intimp.2026.117338_bb0945","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/nrc.2016.71","article-title":"From Krebs to clinic: glutamine metabolism to cancer therapy","volume":"16","author":"Altman","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.intimp.2026.117338_bb0950","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.cmet.2022.04.003","article-title":"Glutaminase inhibition impairs CD8 T cell activation in STK11-\/Lkb1-deficient lung cancer","volume":"34","author":"Best","year":"2022","journal-title":"Cell Metab."},{"issue":"5","key":"10.1016\/j.intimp.2026.117338_bb0955","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109911","article-title":"Regulatory T cell differentiation is controlled by \u03b1KG-induced alterations in mitochondrial metabolism and lipid homeostasis","volume":"37","author":"Matias","year":"2021","journal-title":"Cell Rep."},{"issue":"9","key":"10.1016\/j.intimp.2026.117338_bb0960","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/ni.3796","article-title":"\u03b1-ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming","volume":"18","author":"Liu","year":"2017","journal-title":"Nat. Immunol."},{"issue":"6468","key":"10.1016\/j.intimp.2026.117338_bb0965","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1126\/science.aav2588","article-title":"Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion","volume":"366","author":"Leone","year":"2019","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.intimp.2026.117338_bb0970","doi-asserted-by":"crossref","first-page":"2579S","DOI":"10.3945\/jn.115.226621","article-title":"Arginine metabolism revisited","volume":"146","author":"Morris","year":"2016","journal-title":"J. Nutr."},{"issue":"3","key":"10.1016\/j.intimp.2026.117338_bb0975","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.cell.2016.09.031","article-title":"L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity","volume":"167","author":"Geiger","year":"2016","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.intimp.2026.117338_bb0980","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1182\/blood-2006-06-031856","article-title":"L-arginine availability regulates T-lymphocyte cell-cycle progression","volume":"109","author":"Rodriguez","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.intimp.2026.117338_bb0985","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cellimm.2012.11.018","article-title":"Altered functions of natural killer cells in response to L-Arginine availability","volume":"280","author":"Lamas","year":"2012","journal-title":"Cell. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2026.117338_bb0990","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.trecan.2025.03.008","article-title":"New insights into tryptophan metabolism in cancer","volume":"11","author":"Liu","year":"2025","journal-title":"Trends Cancer"},{"issue":"14","key":"10.1016\/j.intimp.2026.117338_bb0995","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1158\/0008-5472.CAN-22-3042","article-title":"Metformin reprograms tryptophan metabolism to stimulate CD8+ T-cell function in colorectal cancer","volume":"83","author":"Huang","year":"2023","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.intimp.2026.117338_bb1000","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ccell.2017.08.004","article-title":"Enhancing CD8+ T cell fatty acid catabolism within a metabolically challenging tumor microenvironment increases the efficacy of melanoma immunotherapy","volume":"32","author":"Zhang","year":"2017","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb1005","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s13045-021-01200-4","article-title":"Contradictory roles of lipid metabolism in immune response within the tumor microenvironment","volume":"14","author":"Yu","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.intimp.2026.117338_bb1010","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1158\/2326-6066.CIR-19-0702","article-title":"Fatty acid oxidation controls CD8+ tissue-resident memory T-cell survival in gastric adenocarcinoma","volume":"8","author":"Lin","year":"2020","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb1015","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.immuni.2011.12.007","article-title":"Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development","volume":"36","author":"van der Windt","year":"2012","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb1020","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/mco2.6","article-title":"Metabolism in tumor microenvironment: Implications for cancer immunotherapy","volume":"1","author":"Shi","year":"2020","journal-title":"MedComm (2020)"},{"issue":"7","key":"10.1016\/j.intimp.2026.117338_bb1025","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.immuni.2021.05.003","article-title":"Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors","volume":"54","author":"Xu","year":"2021","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.intimp.2026.117338_bb1030","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.cmet.2021.02.015","article-title":"CD36-mediated ferroptosis dampens intratumoral CD8+ T cell effector function and impairs their antitumor ability","volume":"33","author":"Ma","year":"2021","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb1035","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.cmet.2017.06.016","article-title":"Metabolic regulation of T cell longevity and function in tumor immunotherapy","volume":"26","author":"Kishton","year":"2017","journal-title":"Cell Metab."},{"issue":"6","key":"10.1016\/j.intimp.2026.117338_bb1040","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.cell.2013.05.016","article-title":"Posttranscriptional control of T cell effector function by aerobic glycolysis","volume":"153","author":"Chang","year":"2013","journal-title":"Cell"},{"issue":"16","key":"10.1016\/j.intimp.2026.117338_bb1045","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1038\/s41388-020-1216-5","article-title":"The lactate receptor GPR81 promotes breast cancer growth via a paracrine mechanism involving antigen-presenting cells in the tumor microenvironment","volume":"39","author":"Brown","year":"2020","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.intimp.2026.117338_bb1050","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1073\/pnas.1614035114","article-title":"Gpr132 sensing of lactate mediates tumor-macrophage interplay to promote breast cancer metastasis","volume":"114","author":"Chen","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"7779","key":"10.1016\/j.intimp.2026.117338_bb1055","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41586-019-1674-5","article-title":"VISTA is an acidic pH-selective ligand for PSGL-1","volume":"574","author":"Johnston","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb1060","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/s12967-016-1057-8","article-title":"Mesenchymal stromal cells derived from cervical cancer produce high amounts of adenosine to suppress cytotoxic T lymphocyte functions","volume":"14","author":"de Lourdes Mora-Garc\u00eda","year":"2016","journal-title":"J. Transl. Med."},{"issue":"6","key":"10.1016\/j.intimp.2026.117338_bb1065","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1158\/0008-5472.CAN-09-3109","article-title":"CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression","volume":"70","author":"Jin","year":"2010","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.intimp.2026.117338_bb1070","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.3390\/pharmaceutics15051489","article-title":"Mesenchymal stromal cell exosomes mediate M2-like macrophage polarization through CD73\/Ecto-5\u2019-nucleotidase activity","volume":"15","author":"Teo","year":"2023","journal-title":"Pharmaceutics"},{"issue":"105","key":"10.1016\/j.intimp.2026.117338_bb1075","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abo5570","article-title":"Immunogenomic cancer evolution: A framework to understand cancer immunosuppression","volume":"10","author":"Kumagai","year":"2025","journal-title":"Sci. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2026.117338_bb1080","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110914","article-title":"PGE2-EP2\/EP4 signaling elicits immunosuppression by driving the mregDC-Treg axis in inflammatory tumor microenvironment","volume":"39","author":"Thumkeo","year":"2022","journal-title":"Cell Rep."},{"issue":"8","key":"10.1016\/j.intimp.2026.117338_bb1085","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1338239","article-title":"EP4 Antagonism by E7046 diminishes Myeloid immunosuppression and synergizes with Treg-reducing IL-2-Diphtheria toxin fusion protein in restoring anti-tumor immunity","volume":"6","author":"Albu","year":"2017","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.intimp.2026.117338_bb1090","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/cei.12352","article-title":"Activation of the aryl hydrocarbon receptor affects activation and function of human monocyte-derived dendritic cells","volume":"177","author":"Wang","year":"2014","journal-title":"Clin. Exp. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2026.117338_bb1095","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.4049\/jimmunol.0903670","article-title":"An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells","volume":"185","author":"Mezrich","year":"2010","journal-title":"J. Immunol."},{"issue":"7368","key":"10.1016\/j.intimp.2026.117338_bb1100","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nature10491","article-title":"An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor","volume":"478","author":"Opitz","year":"2011","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.intimp.2026.117338_bb1105","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.immuni.2005.03.013","article-title":"GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase","volume":"22","author":"Munn","year":"2005","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.intimp.2026.117338_bb1110","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111193","article-title":"Succinate uptake by T cells suppresses their effector function via inhibition of mitochondrial glucose oxidation","volume":"40","author":"Gudgeon","year":"2022","journal-title":"Cell Rep."},{"issue":"6614","key":"10.1016\/j.intimp.2026.117338_bb1115","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1126\/science.abj5104","article-title":"Oncometabolite d-2HG alters T cell metabolism to impair CD8+ T cell function","volume":"377","author":"Notarangelo","year":"2022","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.intimp.2026.117338_bb1120","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s43018-021-00201-z","article-title":"Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas","volume":"2","author":"Friedrich","year":"2021","journal-title":"Nat. Cancer"},{"issue":"6516","key":"10.1016\/j.intimp.2026.117338_bb1125","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaz0868","article-title":"Physical traits of cancer","volume":"370","author":"Nia","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.intimp.2026.117338_bb1130","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jconrel.2024.10.010","article-title":"Biomaterials to regulate tumor extracellular matrix in immunotherapy","volume":"376","author":"Zhang","year":"2024","journal-title":"J. Control. Release"},{"issue":"16","key":"10.1016\/j.intimp.2026.117338_bb1135","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1007\/s00018-020-03481-3","article-title":"Cellular uptake of collagens and implications for immune cell regulation in disease","volume":"77","author":"J\u00fcrgensen","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"issue":"2","key":"10.1016\/j.intimp.2026.117338_bb1140","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1083\/jcb.201501034","article-title":"The source of matrix-degrading enzymes in human cancer: Problems of research reproducibility and possible solutions","volume":"209","author":"Madsen","year":"2015","journal-title":"J. Cell Biol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb1145","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1038\/s41467-021-22985-5","article-title":"Engineering T cells to enhance 3D migration through structurally and mechanically complex tumor microenvironments","volume":"12","author":"Tabdanov","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb1150","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s40425-019-0556-6","article-title":"Collagen density regulates the activity of tumor-infiltrating T cells","volume":"7","author":"Kuczek","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2026.117338_bb1155","article-title":"Macrophages and extracellular matrix in breast cancer: partners in crime or protective allies?","volume":"24","author":"Deligne","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2026.117338_bb1160","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3389\/fonc.2020.00787","article-title":"Biomechanical contributions to macrophage activation in the tumor microenvironment","volume":"10","author":"Hoffmann","year":"2020","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2026.117338_bb1165","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/nrc3726","article-title":"Hypoxia and the extracellular matrix: drivers of tumour metastasis","volume":"14","author":"Gilkes","year":"2014","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.intimp.2026.117338_bb1170","doi-asserted-by":"crossref","first-page":"R64","DOI":"10.1186\/bcr3458","article-title":"HIF-1\u03b1\/GPER signaling mediates the expression of VEGF induced by hypoxia in breast cancer associated fibroblasts (CAFs)","volume":"15","author":"Francesco","year":"2013","journal-title":"Breast Cancer Res."},{"issue":"6024","key":"10.1016\/j.intimp.2026.117338_bb1175","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1126\/science.1198443","article-title":"CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans","volume":"331","author":"Beatty","year":"2011","journal-title":"Science"},{"issue":"26","key":"10.1016\/j.intimp.2026.117338_bb1180","doi-asserted-by":"crossref","first-page":"8426","DOI":"10.7150\/thno.35434","article-title":"Development of adamantane-conjugated TLR7\/8 agonists for supramolecular delivery and cancer immunotherapy","volume":"9","author":"Rodell","year":"2019","journal-title":"Theranostics"},{"issue":"7","key":"10.1016\/j.intimp.2026.117338_bb1185","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1158\/2326-6066.CIR-16-0309","article-title":"Depletion of tumor-associated macrophages with a CSF-1R kinase inhibitor enhances antitumor immunity and survival induced by DC immunotherapy","volume":"5","author":"Dammeijer","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb1190","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/gutjnl-2015-310514","article-title":"Targeting of tumour-infiltrating macrophages via CCL2\/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma","volume":"66","author":"Li","year":"2017","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.intimp.2026.117338_bb1195","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/annonc\/mdz006","article-title":"The Macrophage \u2018Do not eat me\u2019 signal, CD47, is a clinically validated cancer immunotherapy target","volume":"30","author":"Takimoto","year":"2019","journal-title":"Ann. Oncol."},{"issue":"7769","key":"10.1016\/j.intimp.2026.117338_bb1200","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41586-019-1456-0","article-title":"CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy","volume":"572","author":"Barkal","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb1205","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41590-017-0004-z","article-title":"Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy","volume":"19","author":"Barkal","year":"2018","journal-title":"Nat. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2026.117338_bb1210","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat. Biotechnol."},{"issue":"6","key":"10.1016\/j.intimp.2026.117338_bb1215","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.ccell.2016.04.014","article-title":"CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma","volume":"29","author":"Steele","year":"2016","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.intimp.2026.117338_bb1220","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1158\/0008-5472.CAN-09-3278","article-title":"Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained","volume":"70","author":"Ko","year":"2010","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.intimp.2026.117338_bb1225","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1158\/0008-5472.CAN-15-1490","article-title":"Myeloid-derived suppressor cells express bruton\u2019s tyrosine kinase and can be depleted in tumor-bearing hosts by ibrutinib treatment","volume":"76","author":"Stiff","year":"2016","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.intimp.2026.117338_bb1230","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1158\/1078-0432.CCR-16-1784","article-title":"Selective targeting of myeloid-derived suppressor cells in cancer patients using DS-8273a, an agonistic TRAIL-R2 antibody","volume":"23","author":"Dominguez","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.intimp.2026.117338_bb1235","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1158\/2326-6066.CIR-15-0036","article-title":"Inhibition of fatty acid oxidation modulates immunosuppressive functions of myeloid-derived suppressor cells and enhances cancer therapies","volume":"3","author":"Hossain","year":"2015","journal-title":"Cancer Immunol. Res."},{"issue":"7754","key":"10.1016\/j.intimp.2026.117338_bb1240","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41586-019-1118-2","article-title":"Fatty acid transport protein 2 reprograms neutrophils in cancer","volume":"569","author":"Veglia","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2026.117338_bb1245","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.intimp.2018.08.007","article-title":"Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab","volume":"63","author":"Tobin","year":"2018","journal-title":"Int. Immunopharmacol."},{"issue":"11","key":"10.1016\/j.intimp.2026.117338_bb1250","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.trecan.2022.06.008","article-title":"Therapeutic targeting of regulatory T cells in cancer","volume":"8","author":"Shan","year":"2022","journal-title":"Trends Cancer"},{"issue":"12","key":"10.1016\/j.intimp.2026.117338_bb1255","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/s43018-020-00133-0","article-title":"CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity","volume":"1","author":"Solomon","year":"2020","journal-title":"Nat. Cancer"},{"issue":"10","key":"10.1016\/j.intimp.2026.117338_bb1260","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1007\/s00262-022-03170-z","article-title":"Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy","volume":"71","author":"Sato","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"issue":"9","key":"10.1016\/j.intimp.2026.117338_bb1265","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1080\/14728222.2018.1512588","article-title":"Glucocorticoid-induced TNFR-related gene (GITR) as a therapeutic target for immunotherapy","volume":"22","author":"Riccardi","year":"2018","journal-title":"Expert Opin. Ther. Targets"},{"issue":"5","key":"10.1016\/j.intimp.2026.117338_bb1270","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41591-019-0420-8","article-title":"Rational design of anti-GITR-based combination immunotherapy","volume":"25","author":"Zappasodi","year":"2019","journal-title":"Nat. Med."},{"issue":"22","key":"10.1016\/j.intimp.2026.117338_bb1275","doi-asserted-by":"crossref","first-page":"6614","DOI":"10.1158\/1078-0432.CCR-19-1090","article-title":"A phase I study of the anti-CC chemokine receptor 4 antibody, mogamulizumab, in combination with nivolumab in patients with advanced or metastatic solid tumors","volume":"25","author":"Doi","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.intimp.2026.117338_bb1280","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001749","article-title":"Therapeutic depletion of CCR8+ tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy","volume":"9","author":"van Damme","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.intimp.2026.117338_bb1285","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41590-019-0346-9","article-title":"Adaptive plasticity of IL-10+ and IL-35+ Treg cells cooperatively promotes tumor T cell exhaustion","volume":"20","author":"Sawant","year":"2019","journal-title":"Nat. Immunol."},{"issue":"6005","key":"10.1016\/j.intimp.2026.117338_bb1290","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1126\/science.1195300","article-title":"Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha","volume":"330","author":"Kraman","year":"2010","journal-title":"Science"},{"issue":"50","key":"10.1016\/j.intimp.2026.117338_bb1295","doi-asserted-by":"crossref","first-page":"20212","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.intimp.2026.117338_bb1300","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1158\/2159-8290.CD-20-0775","article-title":"Netrin G1 promotes pancreatic tumorigenesis through cancer-associated fibroblast-driven nutritional support and immunosuppression","volume":"11","author":"Francescone","year":"2021","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb1305","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/s13046-023-02900-0","article-title":"Cancer-associated fibroblasts-derived CXCL12 enhances immune escape of bladder cancer through inhibiting P62-mediated autophagic degradation of PDL1","volume":"42","author":"Zhang","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"22","key":"10.1016\/j.intimp.2026.117338_bb1310","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1158\/0008-5472.CAN-24-0932","article-title":"YAP1 inhibition induces phenotype switching of cancer-associated fibroblasts to tumor suppressive in prostate cancer","volume":"84","author":"Song","year":"2024","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb1315","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13046-020-01611-0","article-title":"Regulation of heterogeneous cancer-associated fibroblasts: the molecular pathology of activated signaling pathways","volume":"39","author":"Yoshida","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.117338_bb1320","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.119983","article-title":"Site-specific MOF-based immunotherapeutic nanoplatforms via synergistic tumor cells-targeted treatment and dendritic cells-targeted immunomodulation","volume":"245","author":"Zhang","year":"2020","journal-title":"Biomaterials"},{"issue":"30","key":"10.1016\/j.intimp.2026.117338_bb1325","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202211415","article-title":"Slimming and reinvigorating tumor-associated dendritic cells with hierarchical lipid rewiring nanoparticles","volume":"35","author":"Xu","year":"2023","journal-title":"Adv. Mater."},{"issue":"2","key":"10.1016\/j.intimp.2026.117338_bb1330","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000772","article-title":"Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model","volume":"8","author":"Lau","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.intimp.2026.117338_bb1335","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20191369","article-title":"Impact of checkpoint blockade on cancer vaccine-activated CD8+ T cell responses","volume":"217","author":"Santos","year":"2020","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb1340","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12943-024-02179-5","article-title":"Current trends in sensitizing immune checkpoint inhibitors for cancer treatment","volume":"23","author":"Wei","year":"2024","journal-title":"Mol. Cancer"},{"issue":"6382","key":"10.1016\/j.intimp.2026.117338_bb1345","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.intimp.2026.117338_bb1350","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113170","article-title":"Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1\/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation","volume":"213","author":"Pan","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.intimp.2026.117338_bb1355","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41419-024-06553-5","article-title":"Metabolic remodeling by the PD-L1 inhibitor BMS-202 significantly inhibits cell malignancy in human glioblastoma","volume":"15","author":"Yang","year":"2024","journal-title":"Cell Death Dis."},{"issue":"5","key":"10.1016\/j.intimp.2026.117338_bb1360","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1016\/j.apsb.2023.02.009","article-title":"Sequential delivery of PD-1\/PD-L1 blockade peptide and IDO inhibitor for immunosuppressive microenvironment remodeling via an MMP-2 responsive dual-targeting liposome","volume":"13","author":"Hu","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"36","key":"10.1016\/j.intimp.2026.117338_bb1365","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1200\/JCO.2008.16.1927","article-title":"Phase I\/II study of ipilimumab for patients with metastatic melanoma","volume":"26","author":"Weber","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.intimp.2026.117338_bb1370","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1038\/s41591-023-02498-y","article-title":"Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial","volume":"29","author":"VanderWalde","year":"2023","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb1375","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40265-022-01827-8","article-title":"Tremelimumab: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.intimp.2026.117338_bb1380","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.trecan.2022.06.009","article-title":"Drug independence and the curability of cancer by combination chemotherapy","volume":"8","author":"Pomeroy","year":"2022","journal-title":"Trends Cancer"},{"issue":"12","key":"10.1016\/j.intimp.2026.117338_bb1385","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.intimp.2026.117338_bb1390","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41568-020-0246-1","article-title":"Inflammatory microenvironment remodelling by tumour cells after radiotherapy","volume":"20","author":"McLaughlin","year":"2020","journal-title":"Nat. Rev. Cancer"},{"issue":"7823","key":"10.1016\/j.intimp.2026.117338_bb1395","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.intimp.2026.117338_bb1400","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41591-020-01206-4","article-title":"Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma","volume":"27","author":"Hu","year":"2021","journal-title":"Nat. Med."},{"issue":"40","key":"10.1016\/j.intimp.2026.117338_bb1405","article-title":"From bench to bedside: emerging paradigms in CAR-T cell therapy for solid malignancies","volume":"12","author":"Chen","year":"2025","journal-title":"Adv. Sci (Weinh)."},{"key":"10.1016\/j.intimp.2026.117338_bb1410","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2025.157488","article-title":"Daidzein reprograms EP300\/CREBBP-deficient immune evasion via targeting the PPAR\u03b3-ANGPT4\/Tie2 axis in hypopharyngeal squamous cell carcinoma","volume":"149","author":"Mao","year":"2025","journal-title":"Phytomedicine"},{"issue":"20","key":"10.1016\/j.intimp.2026.117338_bb1415","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10408","key":"10.1016\/j.intimp.2026.117338_bb1420","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2026.117338_bb1425","first-page":"259","article-title":"Oxygen microcapsules improve immune checkpoint blockade by ameliorating hypoxia condition in pancreatic ductal adenocarcinoma","volume":"20","author":"Wu","year":"2022","journal-title":"Bioact. Mater."},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb1430","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/s12951-021-01144-4","article-title":"Oxygen nanocarrier broke the hypoxia trap of solid tumors and rescued transfection efficiency for gene therapy","volume":"19","author":"Qin","year":"2021","journal-title":"J. Nanobiotechnol."},{"issue":"19","key":"10.1016\/j.intimp.2026.117338_bb1435","doi-asserted-by":"crossref","first-page":"10647","DOI":"10.1002\/anie.202015590","article-title":"Biomimetic nanoemulsion for synergistic photodynamic-immunotherapy against hypoxic breast tumor","volume":"60","author":"Zhang","year":"2021","journal-title":"Angew. Chem. Int. Ed. Eng."},{"issue":"11","key":"10.1016\/j.intimp.2026.117338_bb1440","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1021\/acs.molpharmaceut.2c00432","article-title":"Fluorinated hyaluronic acid encapsulated perfluorocarbon nanoparticles as tumor-targeted oxygen carriers to enhance radiotherapy","volume":"19","author":"Wang","year":"2022","journal-title":"Mol. Pharm."},{"issue":"39","key":"10.1016\/j.intimp.2026.117338_bb1445","article-title":"Engineering endogenous tumor-associated macrophage-targeted biomimetic nano-RBC to reprogram tumor immunosuppressive microenvironment for enhanced chemo-immunotherapy","volume":"33","author":"Wang","year":"2021","journal-title":"Adv. Mater."},{"issue":"9","key":"10.1016\/j.intimp.2026.117338_bb1450","doi-asserted-by":"crossref","DOI":"10.1172\/JCI156774","article-title":"HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy","volume":"132","author":"Salman","year":"2022","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2026.117338_bb1455","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.canlet.2022.01.027","article-title":"HIF-1\u03b1 inhibition promotes the efficacy of immune checkpoint blockade in the treatment of non-small cell lung cancer","volume":"531","author":"Luo","year":"2022","journal-title":"Cancer Lett."},{"issue":"9","key":"10.1016\/j.intimp.2026.117338_bb1460","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1158\/1078-0432.CCR-10-3425","article-title":"Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies","volume":"17","author":"Weiss","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.intimp.2026.117338_bb1465","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.7150\/ijbs.92211","article-title":"Hypoxia-activated selectivity-improved anti-PKM2 antibody combined with prodrug TH-302 for potentiated targeting therapy in hepatocellular carcinoma","volume":"20","author":"Wang","year":"2024","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb1470","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1186\/s12951-023-02203-8","article-title":"TH-302-loaded nanodrug reshapes the hypoxic tumour microenvironment and enhances PD-1 blockade efficacy in gastric cancer","volume":"21","author":"Wang","year":"2023","journal-title":"J. Nanobiotechnol."},{"issue":"10","key":"10.1016\/j.intimp.2026.117338_bb1475","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1158\/1078-0432.CCR-16-0895","article-title":"Molecular pathways: hypoxia-activated prodrugs in cancer therapy","volume":"23","author":"Baran","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.intimp.2026.117338_bb1480","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.it.2021.09.002","article-title":"Metabolic regulation of the cancer-immunity cycle","volume":"42","author":"Patterson","year":"2021","journal-title":"Trends Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2026.117338_bb1485","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ccell.2023.01.009","article-title":"Metabolic programming and immune suppression in the tumor microenvironment","volume":"41","author":"Arner","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2026.117338_bb1490","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113998","article-title":"Cancer-associated fibroblast-derived extracellular vesicles loaded with GLUT1 inhibitor synergize anti-PD-L1 to suppress tumor growth via degrading matrix stiffness and remodeling tumor microenvironment","volume":"385","author":"Wu","year":"2025","journal-title":"J. Control. Release"},{"issue":"8","key":"10.1016\/j.intimp.2026.117338_bb1495","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1158\/1535-7163.MCT-12-0131","article-title":"A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo","volume":"11","author":"Liu","year":"2012","journal-title":"Mol. Cancer Ther."},{"issue":"10","key":"10.1016\/j.intimp.2026.117338_bb1500","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.7150\/ijbs.115610","article-title":"The glucose sensor NSUN2-m5C modification regulates tumor-immune glucose metabolism reprogramming to drive hepatocellular carcinoma evolution","volume":"21","author":"He","year":"2025","journal-title":"Int. J. Biol. Sci."},{"issue":"4","key":"10.1016\/j.intimp.2026.117338_bb1505","doi-asserted-by":"crossref","first-page":"957","DOI":"10.4049\/jimmunol.2000137","article-title":"Metformin and 2-deoxyglucose collaboratively suppress human CD4+ T cell effector functions and activation-induced metabolic reprogramming","volume":"205","author":"Tan","year":"2020","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2026.117338_bb1510","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.cmet.2024.12.007","article-title":"Redirecting glucose flux during in vitro expansion generates epigenetically and metabolically superior T cells for cancer immunotherapy","volume":"37","author":"Frisch","year":"2025","journal-title":"Cell Metab."},{"issue":"3","key":"10.1016\/j.intimp.2026.117338_bb1515","doi-asserted-by":"crossref","first-page":"993","DOI":"10.7150\/thno.104872","article-title":"Metformin-based nanomedicines for reprogramming tumor immune microenvironment","volume":"15","author":"Liu","year":"2025","journal-title":"Theranostics"},{"issue":"49","key":"10.1016\/j.intimp.2026.117338_bb1520","article-title":"Platinum-metformin conjugates acting as promising PD-L1 inhibitors through the AMP-activated protein kinase mediated lysosomal degradation pathway","volume":"63","author":"Liu","year":"2024","journal-title":"Angew. Chem. Int. Ed. Eng."},{"issue":"49","key":"10.1016\/j.intimp.2026.117338_bb1525","doi-asserted-by":"crossref","first-page":"19952","DOI":"10.1074\/jbc.R117.819060","article-title":"Asparagine synthetase: function, structure, and role in disease","volume":"292","author":"Lomelino","year":"2017","journal-title":"J. Biol. Chem."},{"issue":"18","key":"10.1016\/j.intimp.2026.117338_bb1530","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1158\/0008-5472.CAN-23-2910","article-title":"Asparagine dependency is a targetable metabolic vulnerability in TP53-altered castration-resistant prostate cancer","volume":"84","author":"Yoo","year":"2024","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.intimp.2026.117338_bb1535","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/s42255-023-00856-1","article-title":"Asparagine restriction enhances CD8+ T cell metabolic fitness and antitumoral functionality through an NRF2-dependent stress response","volume":"5","author":"Gnanaprakasam","year":"2023","journal-title":"Nat. Metab"},{"issue":"7831","key":"10.1016\/j.intimp.2026.117338_bb1540","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41586-020-2609-x","article-title":"Serine restriction alters sphingolipid diversity to constrain tumour growth","volume":"586","author":"Muthusamy","year":"2020","journal-title":"Nature"},{"issue":"94","key":"10.1016\/j.intimp.2026.117338_bb1545","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adg8817","article-title":"Serine enrichment in tumors promotes regulatory T cell accumulation through sphinganine-mediated regulation of c-Fos","volume":"9","author":"Ma","year":"2024","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.intimp.2026.117338_bb1550","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121018","article-title":"Indoleamine 2,3-dioxygenase (Ido) inhibitors and their nanomedicines for cancer immunotherapy","volume":"276","author":"Guo","year":"2021","journal-title":"Biomaterials"},{"issue":"11","key":"10.1016\/j.intimp.2026.117338_bb1555","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/s41573-022-00538-9","article-title":"The expanding role for small molecules in immuno-oncology","volume":"21","author":"Offringa","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"8","key":"10.1016\/j.intimp.2026.117338_bb1560","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.trecan.2021.04.003","article-title":"Enhancing the efficacy of glutamine metabolism inhibitors in cancer therapy","volume":"7","author":"Yang","year":"2021","journal-title":"Trends Cancer"},{"issue":"3","key":"10.1016\/j.intimp.2026.117338_bb1565","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1158\/1535-7163.MCT-20-0430","article-title":"The glutaminase inhibitor CB-839 (telaglenastat) enhances the antimelanoma activity of T-cell-mediated immunotherapies","volume":"20","author":"Varghese","year":"2021","journal-title":"Mol. Cancer Ther."},{"issue":"24","key":"10.1016\/j.intimp.2026.117338_bb1570","doi-asserted-by":"crossref","first-page":"7608","DOI":"10.1158\/1078-0432.CCR-09-0856","article-title":"Novel inhibitors of fatty acid synthase with anticancer activity","volume":"15","author":"Puig","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.intimp.2026.117338_bb1575","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.1021\/jm2016045","article-title":"New synthetic inhibitors of fatty acid synthase with anticancer activity","volume":"55","author":"Turrado","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.intimp.2026.117338_bb1580","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.addr.2020.07.013","article-title":"Lipids and cancer: emerging roles in pathogenesis, diagnosis and therapeutic intervention","volume":"159","author":"Butler","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"478","key":"10.1016\/j.intimp.2026.117338_bb1585","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau5758","article-title":"Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer","volume":"11","author":"Watt","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.intimp.2026.117338_bb1590","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41590-019-0589-5","article-title":"CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors","volume":"21","author":"Wang","year":"2020","journal-title":"Nat. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2026.117338_bb1595","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.it.2019.06.004","article-title":"Dendritic cell metabolism and function in tumors","volume":"40","author":"Giovanelli","year":"2019","journal-title":"Trends Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2026.117338_bb1600","article-title":"Targeting the mevalonate pathway potentiates NUAK1 inhibition-induced immunogenic cell death and antitumor immunity","volume":"6","author":"Gui","year":"2025","journal-title":"Cell Rep. Med."},{"issue":"2","key":"10.1016\/j.intimp.2026.117338_bb1605","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s42255-020-0174-0","article-title":"Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities","volume":"2","author":"Huang","year":"2020","journal-title":"Nat. Metab."},{"issue":"8","key":"10.1016\/j.intimp.2026.117338_bb1610","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.nano.2018.08.008","article-title":"Enhanced chemo-immunotherapy against melanoma by inhibition of cholesterol esterification in CD8+ T cells","volume":"14","author":"Li","year":"2018","journal-title":"Nanomedicine"},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb1615","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41368-023-00236-1","article-title":"Carcinoma-associated fibroblast-derived lysyl oxidase-rich extracellular vesicles mediate collagen crosslinking and promote epithelial-mesenchymal transition via p-FAK\/p-paxillin\/YAP signaling","volume":"15","author":"Liu","year":"2023","journal-title":"Int. J. Oral. Sci."},{"issue":"12","key":"10.1016\/j.intimp.2026.117338_bb1620","article-title":"A polymeric extracellular matrix nanoremodeler for activatable cancer photo-immunotherapy","volume":"62","author":"Zhang","year":"2023","journal-title":"Angew. Chem. Int. Ed. Eng."},{"issue":"7886","key":"10.1016\/j.intimp.2026.117338_bb1625","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41586-021-04057-2","article-title":"Tumour DDR1 promotes collagen fibre alignment to instigate immune exclusion","volume":"599","author":"Sun","year":"2021","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.intimp.2026.117338_bb1630","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006720","article-title":"A highly selective humanized DDR1 mAb reverses immune exclusion by disrupting collagen fiber alignment in breast cancer","volume":"11","author":"Liu","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"48","key":"10.1016\/j.intimp.2026.117338_bb1635","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202409914","article-title":"Transformable gel-to-nanovaccine enhances cancer immunotherapy via metronomic-like immunomodulation and collagen-mediated paracortex delivery","volume":"36","author":"Jin","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.intimp.2026.117338_bb1640","article-title":"Recombinant humanized type III collagen inhibits ovarian cancer and induces protective anti-tumor immunity by regulating autophagy through GSTP1","volume":"28","author":"Zeng","year":"2024","journal-title":"Mater. Today Bio"},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb1645","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s40364-025-00757-3","article-title":"Extracellular matrix: unlocking new avenues in cancer treatment","volume":"13","author":"Lee","year":"2025","journal-title":"Biomark. Res."},{"issue":"18","key":"10.1016\/j.intimp.2026.117338_bb1650","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202310673","article-title":"Breaking-down tumoral physical barrier by remotely unwrapping metal-polyphenol-packaged hyaluronidase for optimizing photothermal\/photodynamic therapy-induced immune response","volume":"36","author":"Sun","year":"2024","journal-title":"Adv. Mater."},{"issue":"3","key":"10.1016\/j.intimp.2026.117338_bb1655","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008431","article-title":"An oncolytic vaccinia virus encoding hyaluronidase reshapes the extracellular matrix to enhance cancer chemotherapy and immunotherapy","volume":"12","author":"Wang","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb1660","doi-asserted-by":"crossref","DOI":"10.1080\/20013078.2019.1670893","article-title":"Degradation of tumour stromal hyaluronan by small extracellular vesicle-PH20 stimulates CD103+ dendritic cells and in combination with PD-L1 blockade boosts anti-tumour immunity","volume":"8","author":"Hong","year":"2019","journal-title":"J. Extracell. Vesicles"},{"issue":"15","key":"10.1016\/j.intimp.2026.117338_bb1665","doi-asserted-by":"crossref","first-page":"10542","DOI":"10.1021\/acsnano.3c12615","article-title":"Zinc-iron bimetallic peroxides modulate the tumor stromal microenvironment and enhance cell immunogenicity for enhanced breast cancer immunotherapy therapy","volume":"18","author":"Lu","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.intimp.2026.117338_bb1670","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113784","article-title":"Design strategies for hyaluronic acid-based drug delivery systems in cancer immunotherapy","volume":"383","author":"Rodella","year":"2025","journal-title":"J. Control. Release"},{"issue":"8","key":"10.1016\/j.intimp.2026.117338_bb1675","doi-asserted-by":"crossref","first-page":"7475","DOI":"10.1021\/acsnano.2c12463","article-title":"Nattokinase-mediated regulation of tumor physical microenvironment to enhance chemotherapy, radiotherapy, and CAR-T therapy of solid tumor","volume":"17","author":"Zhang","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.intimp.2026.117338_bb1680","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jconrel.2024.07.076","article-title":"Engineered bacteria breach tumor physical barriers to enhance radio-immunotherapy","volume":"373","author":"Zhang","year":"2024","journal-title":"J. Control. Release"},{"issue":"5","key":"10.1016\/j.intimp.2026.117338_bb1685","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004076","article-title":"Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients na\u00efve or experienced for immune checkpoint blockade","volume":"10","author":"Gomez-Roca","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb1690","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011284","article-title":"Phase 1b\/2 study of BMS-813160, a CCR2\/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer","volume":"14","author":"Le","year":"2026","journal-title":"J. Immunother. Cancer"},{"issue":"12","key":"10.1016\/j.intimp.2026.117338_bb1695","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1158\/1078-0432.CCR-22-3313","article-title":"Eganelisib, a first-in-class PI3K\u03b3 inhibitor, in patients with advanced solid tumors: results of the phase 1\/1b MARIO-1 trial","volume":"29","author":"Hong","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.intimp.2026.117338_bb1700","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010634","article-title":"Phase I study on neoadjuvant combination immunotherapy with mogamulizumab and nivolumab for solid tumors","volume":"13","author":"Jinushi","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.intimp.2026.117338_bb1705","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s43018-026-01157-8","article-title":"Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial","volume":"7","author":"Melero","year":"2026","journal-title":"Nat. Cancer"},{"issue":"13","key":"10.1016\/j.intimp.2026.117338_bb1710","first-page":"1546","article-title":"Three-year overall survival with nivolumab plus relatlimab in advanced melanoma from RELATIVITY-047","volume":"43","author":"Tawbi","year":"2025","journal-title":"Clin. Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2026.117338_bb1715","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.annonc.2021.11.002","article-title":"First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer","volume":"33","author":"Niu","year":"2022","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117338_bb1720","doi-asserted-by":"crossref","DOI":"10.1155\/jimr\/7864229","article-title":"Next-generation immune checkpoints and tumor microenvironment modulation in cancer immunotherapy","volume":"2026","author":"Bautista","year":"2026","journal-title":"J. Immunol. Res."},{"issue":"11","key":"10.1016\/j.intimp.2026.117338_bb1725","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010006","article-title":"Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumors","volume":"12","author":"Taylor","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"11","key":"10.1016\/j.intimp.2026.117338_bb1730","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1158\/2159-8290.CD-23-0436","article-title":"Neoadjuvant durvalumab alone or combined with novel immuno-oncology agents in resectable lung cancer: the phase II NeoCOAST platform trial","volume":"13","author":"Cascone","year":"2023","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.intimp.2026.117338_bb1735","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/s41416-024-02796-3","article-title":"COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer","volume":"131","author":"Segal","year":"2024","journal-title":"Br. J. Cancer"},{"issue":"8","key":"10.1016\/j.intimp.2026.117338_bb1740","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2026.117338_bb1745","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104536","article-title":"A phase I\/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer","volume":"10","author":"Gouda","year":"2025","journal-title":"ESMO Open"},{"issue":"27","key":"10.1016\/j.intimp.2026.117338_bb1750","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1200\/JCO.20.00590","article-title":"Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma","volume":"38","author":"Cutsem","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"25","key":"10.1016\/j.intimp.2026.117338_bb1755","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO-25-00112","article-title":"Efficacy and safety of avutometinib \u00b1 defactinib in recurrent low-grade serous ovarian cancer: primary analysis of ENGOT-OV60\/GOG-3052\/RAMP 201","volume":"43","author":"Banerjee","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2026.117338_bb1760","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1634\/theoncologist.2017-0024","article-title":"A phase II randomized, double-blind, placebo-controlled study of simtuzumab or placebo in combination with gemcitabine for the first-line treatment of pancreatic adenocarcinoma","volume":"22","author":"Benson","year":"2017","journal-title":"Oncologist"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926011859?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926011859?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:30:04Z","timestamp":1790436604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926011859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":352,"alternative-id":["S1567576926011859"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117338","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting immunosuppressive tumor microenvironment to combat immunotherapy resistance: From mechanistic insights to therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117338","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117338"}}